BioCentury | Nov 4, 2016
Emerging Company Profile

Exploiting alpha-GAL

...glycolipids Disease focus: Cancer Clinical status: Preclinical Founded: 2013 by Uri Galili, Animatrix Capital LLP, Loxbridge Research LLP...
BioCentury | May 28, 2015
Product R&D

Altermune's Alphamers

...Westby is CEO of Agalimmune Ltd., which was founded in 2013 with partial backing from Loxbridge Research LLP...
BioCentury | Jul 28, 2014
Clinical News

Alpha-gal glycolipids: Phase I data

...another Phase I trial in melanoma triggered a L1.2 million ($2 million) milestone payment from Loxbridge Research LLP...
BioCentury | Dec 9, 2013
Company News

Agalimmune cancer news

Loxbridge Research LLP and Animatrix Capital LLP founded newco Agalimmune to develop immunotherapies to treat cancer, with a focus on solid tumors. Agalimmune has rights to Alphaject technology from the University of Massachusetts Medical Clinic....
Items per page:
1 - 4 of 4
BioCentury | Nov 4, 2016
Emerging Company Profile

Exploiting alpha-GAL

...glycolipids Disease focus: Cancer Clinical status: Preclinical Founded: 2013 by Uri Galili, Animatrix Capital LLP, Loxbridge Research LLP...
BioCentury | May 28, 2015
Product R&D

Altermune's Alphamers

...Westby is CEO of Agalimmune Ltd., which was founded in 2013 with partial backing from Loxbridge Research LLP...
BioCentury | Jul 28, 2014
Clinical News

Alpha-gal glycolipids: Phase I data

...another Phase I trial in melanoma triggered a L1.2 million ($2 million) milestone payment from Loxbridge Research LLP...
BioCentury | Dec 9, 2013
Company News

Agalimmune cancer news

Loxbridge Research LLP and Animatrix Capital LLP founded newco Agalimmune to develop immunotherapies to treat cancer, with a focus on solid tumors. Agalimmune has rights to Alphaject technology from the University of Massachusetts Medical Clinic....
Items per page:
1 - 4 of 4